Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03465709 · ClinicalTrials.gov registry record · Phase 1
Pegcetacoplan (APL-2) in Neovascular AMD
A Phase 1 study, sponsored by Apellis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT03465709: Clinical Trial Phase 1 study, sponsored by Apellis Pharmaceuticals.
NCT03465709 is a Phase 1 study that was terminated before completion, run by Apellis Pharmaceuticals. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03465709, a Phase 1 study, was terminated before completion, sponsored by Apellis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
Safety Assessment of Pegcetacoplan in Patients with Neovascular AMD
Primary Outcome
TEAEs were defined as those adverse events (AEs) that developed or worsened after the first dose of study drug, up to 30 days after the last dose. The severity of the TEAEs was classified as mild (asymptomatic/mild symptoms); moderate (minimal, local/non-invasive intervention indicated); severe (medically significant but not life-threatening); life-threatening or leading to death. The number of subjects experiencing 1 TEAE in each category is presented. A maximum of 7 injections of pegcetacoplan
Interventions
- DRUG Pegcetacoplan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-02-14 |
| Est. Completion | 2019-04-05 |
| Phase | Phase 1 |
Why NCT03465709 stopped before completion
NCT03465709 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 1 intervention - of which Pegcetacoplan is the first listed.
NCT03465709 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03465709 about?
NCT03465709 is a clinical study titled "Pegcetacoplan (APL-2) in Neovascular AMD". Safety Assessment of Pegcetacoplan in Patients with Neovascular AMD
What is the current status of trial NCT03465709?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2018-02-14. Estimated completion is 2019-04-05.
What interventions are being tested in trial NCT03465709?
The interventions under investigation include: Pegcetacoplan (DRUG).
Who is sponsoring clinical trial NCT03465709?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03465709's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI